Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Tyrosine Kinase Inhibitor Therapy for Brain Metastases in Non-Small-Cell Lung Cancer: A Primer for Radiologists

Tyrosine Kinase Inhibitor Therapy for Brain Metastases in Non-Small-Cell Lung Cancer: A Primer... REVIEW ARTICLE Tyrosine Kinase Inhibitor Therapy for Brain Metastases in Non-Small-Cell Lung Cancer: A Primer for Radiologists C. Dodson, T.J. Richards, D.A. Smith, and N.H. Ramaiya ABSTRACT SUMMARY: Treatment options for patients who develop brain metastases secondary to non-small-cell lung cancer have rapidly expanded in recent years. As a key adjunct to surgical and radiation therapy options, systemic therapies are now a critical compo- nent of the oncologic management of metastatic CNS disease in many patients with non-small-cell lung cancer. The aim of this review article was to provide a guide for radiologists, outlining the role of systemic therapies in metastatic non-small-cell lung can- cer, with a focus on tyrosine kinase inhibitors. The critical role of the blood-brain barrier in the development of systemic therapies will be described. The final sections of this review will provide an overview of current imaging-based guidelines for therapy response. The utility of the Response Assessment in Neuro-Oncology criteria will be discussed, with a focus on how to use the response criteria in the assessment of patients treated with systemic and traditional therapies. ABBREVIATIONS: ALK ¼ anaplastic lymphoma kinase; CTLA-4 ¼ cytotoxic T-lymphocyte-associated protein 4; EGFR ¼ epidermal growth factor receptor; EML4 ¼ echinoderm http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Neuroradiology American Journal of Neuroradiology

Tyrosine Kinase Inhibitor Therapy for Brain Metastases in Non-Small-Cell Lung Cancer: A Primer for Radiologists

Download PDF
13 pages

Loading next page...
 
/lp/american-journal-of-neuroradiology/tyrosine-kinase-inhibitor-therapy-for-brain-metastases-in-non-small-rLUYDyJpRM

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
American Journal of Neuroradiology
Copyright
© 2020 by American Journal of Neuroradiology
ISSN
0195-6108
eISSN
1936-959X
DOI
10.3174/ajnr.A6477
Publisher site
See Article on Publisher Site

Abstract

REVIEW ARTICLE Tyrosine Kinase Inhibitor Therapy for Brain Metastases in Non-Small-Cell Lung Cancer: A Primer for Radiologists C. Dodson, T.J. Richards, D.A. Smith, and N.H. Ramaiya ABSTRACT SUMMARY: Treatment options for patients who develop brain metastases secondary to non-small-cell lung cancer have rapidly expanded in recent years. As a key adjunct to surgical and radiation therapy options, systemic therapies are now a critical compo- nent of the oncologic management of metastatic CNS disease in many patients with non-small-cell lung cancer. The aim of this review article was to provide a guide for radiologists, outlining the role of systemic therapies in metastatic non-small-cell lung can- cer, with a focus on tyrosine kinase inhibitors. The critical role of the blood-brain barrier in the development of systemic therapies will be described. The final sections of this review will provide an overview of current imaging-based guidelines for therapy response. The utility of the Response Assessment in Neuro-Oncology criteria will be discussed, with a focus on how to use the response criteria in the assessment of patients treated with systemic and traditional therapies. ABBREVIATIONS: ALK ¼ anaplastic lymphoma kinase; CTLA-4 ¼ cytotoxic T-lymphocyte-associated protein 4; EGFR ¼ epidermal growth factor receptor; EML4 ¼ echinoderm

Journal

American Journal of Neuroradiology – American Journal of Neuroradiology

Published: May 1, 2020

There are no references for this article.